Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

11028	Companies
241689	Keywords
170152	Articles
130124	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 08/12/2025 at 07:05, 1 year 1 month ago

Newron Initiates Phase III ENIGMA-TRS Study for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Phase III Study TRS Therapy
PRESS RELEASE

published on 08/12/2025 at 07:00, 1 year 1 month ago

Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 08/11/2025 at 07:05, 1 year 1 month ago

Newron Pharmaceuticals' Evenamide Shows Promise in Schizophrenia Treatment

Newron Pharmaceuticals Schizophrenia Treatment Evenamide Research Glutamate Modulation Neuropsychopharmacology Study
PRESS RELEASE

published on 08/11/2025 at 07:00, 1 year 1 month ago

Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Newron Pharmaceuticals notes new preclinical research indicating evenamide may improve schizophrenia-related dysfunction by targeting hippocampal pathology. Study shows potential for novel therapeutic strategy

Schizophrenia Newron Pharmaceuticals Evenamide Preclinical Research Hippocampus
BRIEF

published on 05/12/2025 at 07:05, 1 year 4 months ago

Newron's ENIGMA-TRS Phase III Program Approved for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Treatment-resistant Schizophrenia Glutamatergic Modulation
PRESS RELEASE

published on 05/12/2025 at 07:00, 1 year 4 months ago

Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals announces approval for pivotal Phase III ENIGMA-TRS program evaluating evenamide as add-on therapy in treatment-resistant schizophrenia patients. Study results expected in Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 04/01/2025 at 07:05, 1 year 5 months ago

Newron Pharmaceuticals Reports 2024 Financial Results, Previews 2025

Financial Results Evenamide Development Schizophrenia Treatment Licensing Agreements Outlook 2025
PRESS RELEASE

published on 04/01/2025 at 07:00, 1 year 5 months ago

Newron presents 2024 financial results and provides 2025 outlook
Newron Pharmaceuticals presents 2024 financial results and 2025 outlook, focusing on evenamide development for schizophrenia treatment and strategic licensing agreements

Financial Results Newron Pharmaceuticals Evenamide Licensing Agreements 2025 Outlook
BRIEF

published on 03/24/2025 at 17:50, 1 year 5 months ago

Newron Pharmaceuticals Nominates Dr. Chris Martin as Independent Chairman

Board Of Directors Newron Pharmaceuticals Chris Martin Biopharma Leadership Schizophrenia Therapy
PRESS RELEASE

published on 03/24/2025 at 17:45, 1 year 5 months ago

Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
Newron Pharmaceuticals S.p.A. proposes Chris Martin, ex-CEO of ADC Therapeutics, as Independent Chairman succeeding Dr. Köstlin after 12 years. Martin an experienced biopharma leader

Chairman Biopharma Newron Pharmaceuticals Chris Martin ADC Therapeutics

Accesswire

Published on 09/19/2026 at 00:55, 2 days ago

Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 2 days 1 hour ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 2 days 3 hours ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 2 days 4 hours ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 2 days 10 hours ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

View all ACCESSWIRE

EQS Group

Published on 09/20/2026 at 15:10, 10 hours 15 minutes ago

MSITEK Participates in New York Fashion Week Retail Innovation Lab
Published on 09/20/2026 at 09:05, 16 hours 20 minutes ago

Huawei Digital Power Showcases Multi-Scenario Solutions Featuring Grid Forming and AI at IDEE 2026
Published on 09/20/2026 at 06:30, 18 hours 55 minutes ago

Huawei Grid-Interactive AIDC Solution: Shaping the New Paradigm of AI Infrastructure
Published on 09/20/2026 at 04:35, 20 hours 50 minutes ago

How to Achieve Sustainable Power Without Changing Your Existing Backup System
Published on 09/19/2026 at 16:40, 1 day 8 hours ago

2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens

Les Echos

Published on 09/18/2026 at 18:34, 2 days 6 hours ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 2 days 7 hours ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 2 days 7 hours ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 3 days 7 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 4 days 4 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE